At Venn Therapeutics, we are dedicated to developing the next wave of disruptive immuno-oncology therapies. Our initial programs represent a mechanistically diverse approach to overcoming the immunosuppresive tumor microenvironment and facilitating the infiltration of cytotoxic CD8+ lymphocytes.

Pursuing novel therapies in STING (Stimulator of Interferon Genes) agonists and potentially disruptive Oncolytic Virus therapies using Bovine Herpes Virus.

Medical equipment